parenteral solution of sodium chloride and riboflavin in water for injection (wfi) intended for subcutaneous injection

DRUG2 trials

Sponsors

Ionis Pharmaceuticals Inc.

Conditions

Severe Hypertriglyceridemia.Severe hypertryglyceridemia

Phase 3

ISIS 678354-CS6 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients with Severe Hypertriglyceridemia

CompletedCTIS2022-501420-20-00

Ionis Pharmaceuticals Inc.Severe hypertryglyceridemia

Start: 2023-05-17End: 2025-09-12Target: 248Updated: 2025-09-03

ISIS 678354-CS5: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia.

CompletedCTIS2024-510696-38-00

Ionis Pharmaceuticals Inc.Severe Hypertriglyceridemia.

Start: 2022-03-08End: 2025-05-28Target: 368Updated: 2025-06-30